-1753896225110.webp&w=3840&q=75)
2025 NOSCM | Frontline Therapy for Transplant Eligible Multiple Myeloma Patients
Overview
Dr. Vincent Rajkumar discussed newly diagnosed multiple myeloma in transplant-eligible patients, noting 20–25% are now high risk. Quadruplet regimens like Dara-VRd show strong outcomes, with 90% 4-year survival. Early transplant is key for high-risk cases; lenalidomide remains standard for maintenance.
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
S. Vincent Rajkumar, MD
Date of Release
July 30th, 2025
-1753896303755.webp&w=3840&q=75)
